Eli Lilly & Co.
Revenue Breakdown
| Fiscal Year | Zyprexa | Cialis | Alimta | Humalog | Humulin | Gemzar | Evista | Forteo | Strattera | Symbyax | Erbitux | Byetta | Trad jenta | Effient | Jardiance | Trulicity | Taltz | Olumiant | Verzenio | Emgality | Tyvyt | Cyramza | Baqsimi | Retevmo | Bebtelovimab | Mounjaro | Jaypirca | Zepbound | Omvoh | Ebglyss | Kisunla | Animal Health | Collaboration and Other Revenue | Other Pharmaceutical Products |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2021 | $0 | $810.0M | $1.23B | $2.45B | $1.22B | $0 | $0 | $802.2M | $790.0M | $0 | $0 | $0 | $0 | $0 | $1.49B | $6.47B | $2.21B | $111.4M | $1.35B | $550.8M | $0 | $1.03B | $0 | $0 | $2.24B | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $378.1M | $4.97B |
| FY2022 | $0 | $0 | $927.8M | $2.06B | $1.02B | $0 | $0 | $612.9M | $0 | $0 | $0 | $0 | $0 | $0 | $2.06B | $7.44B | $2.48B | $179.2M | $2.01B | $650.9M | $0 | $971.0M | $0 | $0 | $1.20B | $482.5M | $0 | $0 | $0 | $0 | $0 | $0 | $511.2M | $5.04B |
| FY2023 | $0 | $0 | $226.7M | $1.63B | $796.8M | $0 | $0 | $580.4M | $0 | $0 | $0 | $0 | $0 | $0 | $2.57B | $7.13B | $2.76B | $168.5M | $3.86B | $678.4M | $0 | $1.01B | $0 | $0 | $0 | $5.16B | $128.0M | $175.8M | $0 | $0 | $0 | $0 | $1.09B | $6.15B |
| FY2024 | $0 | $0 | $0 | $1.28B | $627.5M | $0 | $0 | $466.8M | $0 | $0 | $0 | $0 | $0 | $0 | $3.23B | $6.23B | $3.10B | $154.2M | $5.08B | $746.5M | $0 | $1.08B | $0 | $0 | $0 | $11.54B | $320.0M | $3.03B | $0 | $0 | $0 | $0 | $1.30B | $6.85B |
| FY2025 | $0 | $0 | $0 | $1.10B | $541.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.81B | $5.82B | $3.41B | $142.3M | $6.21B | $821.6M | $0 | $1.12B | $0 | $0 | $0 | $17.53B | $481.0M | $10.21B | $112.4M | $98.6M | $85.2M | $0 | $1.65B | $12.03B |